Umbilical Cord–Derived MSC Therapy Shows Multi-Year Benefits in Retinitis Pigmentosa

Published in Stem Cells Translational Medicine (Oxford Academic)

A large open-access study reports long-term safety and functional gains after suprachoroidal implantation of umbilical cord–derived mesenchymal stem cells in retinitis pigmentosa. Across 669 eyes with up to four years of follow-up, investigators observed significant improvements in best-corrected visual acuity, visual field metrics, and multifocal ERG central ring amplitudes, with no serious ocular or systemic complications reported. The findings support UC-MSC therapy as a feasible approach for stabilizing disease and improving visual function, while underscoring the need for continued studies across disease stages and with advanced functional testing.

👉 Read the full article: Evaluating the long-term efficacy of umbilical cord-derived mesenchymal stem cell therapy in retinitis pigmentosa: findings from a 1-to-4-year follow-up

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.